1
|
Renalase: a novel regulator of cardiometabolic and renal diseases. Hypertens Res 2022; 45:1582-1598. [PMID: 35941358 PMCID: PMC9358379 DOI: 10.1038/s41440-022-00986-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Revised: 04/26/2022] [Accepted: 06/05/2022] [Indexed: 11/13/2022]
Abstract
Renalase is a ~38 kDa flavin-adenine dinucleotide (FAD) domain-containing protein that can function as a cytokine and an anomerase. It is emerging as a novel regulator of cardiometabolic diseases. Expressed mainly in the kidneys, renalase has been reported to have a hypotensive effect and may control blood pressure through regulation of sympathetic tone. Furthermore, genetic variations in the renalase gene, such as a functional missense polymorphism (Glu37Asp), have implications in the cardiovascular and renal systems and can potentially increase the risk of cardiometabolic disorders. Research on the physiological functions and biochemical actions of renalase over the years has indicated a role for renalase as one of the key proteins involved in various disease states, such as diabetes, impaired lipid metabolism, and cancer. Recent studies have identified three transcription factors (viz., Sp1, STAT3, and ZBP89) as key positive regulators in modulating the expression of the human renalase gene. Moreover, renalase is under the post-transcriptional regulation of two microRNAs (viz., miR-29b, and miR-146a), which downregulate renalase expression. While renalase supplementation may be useful for treating hypertension, inhibition of renalase signaling may be beneficial to patients with cancerous tumors. However, more incisive investigations are required to unravel the potential therapeutic applications of renalase. Based on the literature pertaining to the function and physiology of renalase, this review attempts to consolidate and comprehend the role of renalase in regulating cardiometabolic and renal disorders. ![]()
Collapse
|
2
|
Wang Y, Chen C, Hu GL, Chu C, Zhang XY, Du MF, Zou T, Zhou Q, Liao YY, Ma Q, Wang KK, Sun Y, Wang D, Yan Y, Li Y, Jia H, Niu ZJ, Zhang X, Wang L, Man ZY, Gao WH, Li CH, Zhang J, Gao K, Li HX, Chang J, Desir GV, Lu WH, Mu JJ. Associations of Renalase With Blood Pressure and Hypertension in Chinese Adults. Front Cardiovasc Med 2022; 9:800427. [PMID: 35282385 PMCID: PMC8907541 DOI: 10.3389/fcvm.2022.800427] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2021] [Accepted: 01/31/2022] [Indexed: 12/11/2022] Open
Abstract
Objective Renalase, a novel secretory flavoprotein with amine oxidase activity, is secreted into the blood by the kidneys and is hypothesized to participate in blood pressure (BP) regulation. We investigated the associations of renalase with BP and the risk of hypertension by examining renalase single nucleopeptide polymorphism (SNPs), serum renalase levels, and renal expression of renalase in humans. Methods ① Subjects (n = 514) from the original Baoji Salt-Sensitive Study cohort were genotyped to investigate the association of renalase SNPs with longitudinal BP changes and the risk of hypertension during 14 years of follow-up. ② Two thousand three hundred and ninety two participants from the Hanzhong Adolescent Hypertension Study cohort were used to examine the association of serum renalase levels with hypertension. Renalase expression in renal biopsy specimens from 193 patients were measured by immunohistochemistry. ③ Renalase expression was compared in hypertensive vs. normotensive patients. Results ① SNP rs7922058 was associated with 14-year change in systolic BP, and rs10887800, rs796945, rs1935582, rs2296545, and rs2576178 were significantly associated with 14-year change in diastolic BP while rs1935582 and rs2576178 were associated with mean arterial pressure change over 14 years. In addition, SNPs rs796945, rs1935582, and rs2576178 were significantly associated with hypertension incidence. Gene-based analysis found that renalase gene was significantly associated with hypertension incidence over 14-year follow-up after adjustment for multiple measurements. ② Hypertensive subjects had higher serum renalase levels than normotensive subjects (27.2 ± 0.4 vs. 25.1 ± 0.2 μg/mL). Serum renalase levels and BPs showed a linear correlation. In addition, serum renalase was significantly associated with the risk of hypertension [OR = 1.018 (1.006–1.030)]. ③ The expression of renalase in human renal biopsy specimens significantly decreased in hypertensive patients compared to non-hypertensive patients (0.030 ± 0.001 vs. 0.038 ± 0.004). Conclusions These findings indicate that renalase may play an important role in BP progression and development of hypertension.
Collapse
Affiliation(s)
- Yang Wang
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China
| | - Chen Chen
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China
| | - Gui-Lin Hu
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Chao Chu
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China
| | - Xiao-Yu Zhang
- Department of Cardiology, Northwest Women's and Children's Hospital of Xi'an Jiaotong University Health Science Center, Xi'an, China
| | - Ming-Fei Du
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Ting Zou
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Qing Zhou
- National Engineering Research Center for Beijing Biochip Technology, Beijing, China
| | - Yue-Yuan Liao
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China
| | - Qiong Ma
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China
| | - Ke-Ke Wang
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China
| | - Yue Sun
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China
| | - Dan Wang
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Yu Yan
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China
| | - Yan Li
- Department of Nephrology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Hao Jia
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Ze-Jiaxin Niu
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Xi Zhang
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Lan Wang
- Department of Cardiology, Xi'an International Medical Center Hospital, Xi'an, China
| | - Zi-Yue Man
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China
| | - Wei-Hua Gao
- Department of Cardiology, Xi'an No.1 Hospital, Xi'an, China
| | - Chun-Hua Li
- Department of Ophthalmology, Xi'an People's Hospital, Xi'an, China
| | - Jie Zhang
- Department of Cardiology, Xi'an People's Hospital, Xi'an, China
| | - Ke Gao
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Hui-Xian Li
- Department of Nephrology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - John Chang
- Department of Medicine, Yale University School of Medicine, New Haven, CT, United States
- Department of Medicine, Veterans Administration Healthcare System, West Haven, CT, United States
| | - Gary V. Desir
- Department of Medicine, Yale University School of Medicine, New Haven, CT, United States
- Department of Medicine, Veterans Administration Healthcare System, West Haven, CT, United States
| | - Wan-Hong Lu
- Department of Nephrology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- *Correspondence: Wan-Hong Lu
| | - Jian-Jun Mu
- Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China
- Jian-Jun Mu
| |
Collapse
|
3
|
Wiśniewska M, Serwin N, Dziedziejko V, Marchelek-Myśliwiec M, Dołęgowska B, Domański L, Ciechanowski K, Safranow K, Gołębiowski T, Pawlik A. The Effect of Bilateral Nephrectomy on Renalase and Catecholamines in Hemodialysis Patients. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021; 18:ijerph18126282. [PMID: 34200667 PMCID: PMC8296035 DOI: 10.3390/ijerph18126282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 06/02/2021] [Accepted: 06/08/2021] [Indexed: 12/05/2022]
Abstract
Background/Aims: Renalase is an enzyme with monoamine oxidase activity that metabolizes catecholamines; therefore, it has a significant influence on arterial blood pressure regulation and the development of cardiovascular diseases. Renalase is mainly produced in the kidneys. Nephrectomy and hemodialysis (HD) may alter the production and metabolism of renalase. The aim of this study was to examine the effect of bilateral nephrectomy on renalase levels in the serum and erythrocytes of hemodialysis patients. Methods: This study included 27 hemodialysis patients post-bilateral nephrectomy, 46 hemodialysis patients without nephrectomy but with chronic kidney disease and anuria and 30 healthy subjects with normal kidney function. Renalase levels in the serum and erythrocytes were measured using an ELISA kit. Results: Serum concentrations of renalase were significantly higher in post-bilateral nephrectomy patients when compared with those of control subjects (101.1 ± 65.5 vs. 19.6 ± 5.0; p < 0.01). Additionally, renalase concentrations, calculated per gram of hemoglobin, were significantly higher in patients after bilateral nephrectomy in comparison with those of healthy subjects (994.9 ± 345.5 vs. 697.6 ± 273.4, p = 0.015). There were no statistically significant differences in plasma concentrations of noradrenaline or adrenaline. In contrast, the concentration of dopamine was significantly lower in post-nephrectomy patients when compared with those of healthy subjects (116.8 ± 147.7 vs. 440.9 ± 343.2, p < 0.01). Conclusions: Increased serum levels of renalase in post-bilateral nephrectomy hemodialysis patients are likely related to production in extra-renal organs as a result of changes in the cardiovascular system and hypertension.
Collapse
Affiliation(s)
- Magda Wiśniewska
- Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; (M.W.); (M.M.-M.); (L.D.); (K.C.)
| | - Natalia Serwin
- Immunology and Laboratory Medicine, Department of Microbiology, Pomeranian Medical University, 70-111 Szczecin, Poland; (N.S.); (B.D.)
| | - Violetta Dziedziejko
- Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland; (V.D.); (K.S.)
| | - Małgorzata Marchelek-Myśliwiec
- Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; (M.W.); (M.M.-M.); (L.D.); (K.C.)
| | - Barbara Dołęgowska
- Immunology and Laboratory Medicine, Department of Microbiology, Pomeranian Medical University, 70-111 Szczecin, Poland; (N.S.); (B.D.)
| | - Leszek Domański
- Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; (M.W.); (M.M.-M.); (L.D.); (K.C.)
| | - Kazimierz Ciechanowski
- Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; (M.W.); (M.M.-M.); (L.D.); (K.C.)
| | - Krzysztof Safranow
- Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland; (V.D.); (K.S.)
| | - Tomasz Gołębiowski
- Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland;
| | - Andrzej Pawlik
- Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland
- Correspondence:
| |
Collapse
|
4
|
Li Y, Wu W, Liu W, Zhou M. Roles and mechanisms of renalase in cardiovascular disease: A promising therapeutic target. Biomed Pharmacother 2020; 131:110712. [PMID: 32916539 DOI: 10.1016/j.biopha.2020.110712] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Revised: 08/28/2020] [Accepted: 08/30/2020] [Indexed: 12/16/2022] Open
Abstract
Cardiovascular disease (CVD) is prevalent worldwide and remains a leading cause of death. Although substantial progress has been made in the diagnosis and treatment of CVD, the prognosis remains unsatisfactory. Renalase is a newly discovered cytokine that is synthesized by the kidney and then secreted into blood. Numerous studies have suggested the efficacy of renalase in treating CVD by metabolizing catecholamines in the circulatory system. As a new biomarker of heart disease, renalase is normally recognized as a signalling molecule that activates cytoprotective intracellular signals to lower blood pressure, protect ischaemic heart muscle and promote atherosclerotic plaque stability in CVD, which subsequently improves cardiac function. Due to its important regulatory role in the circulatory system, renalase has gradually become a potential target in the treatment of CVD. This review summarizes the structure, mechanism and function of renalase in CVD, thereby providing preclinical evidence for alternative approaches and new prospects in the development of renalase-related drugs against CVD.
Collapse
Affiliation(s)
- Yue Li
- Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Traditional Chinese Medicine, Beijing, 100010, China
| | - Weidong Wu
- London Metropolitan University, London, N7 8DB, United Kingdom
| | - Weihong Liu
- Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Traditional Chinese Medicine, Beijing, 100010, China
| | - Mingxue Zhou
- Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Traditional Chinese Medicine, Beijing, 100010, China.
| |
Collapse
|
5
|
Serwin NM, Wiśniewska M, Cecerska-Heryć E, Safranow K, Skwirczyńska E, Dołęgowska B. Serum-to-urine renalase ratio and renalase fractional excretion in healthy adults and chronic kidney disease patients. BMC Nephrol 2020; 21:77. [PMID: 32131757 PMCID: PMC7057639 DOI: 10.1186/s12882-020-01737-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Accepted: 02/24/2020] [Indexed: 01/11/2023] Open
Abstract
Background Renalase is a flavoprotein that plays a protective role in chronic kidney disease (CKD) and cardiovascular diseases. The secretion and way of action of this protein are still discussed. The aim of our study was to estimate the balance between serum and urine renalase in healthy individuals and CKD patients, using two parameters: fractional excretion (FE) and serum-to-urine renalase ratio (StURR). Methods Our study involved 28 healthy volunteers and 62 patients with CKD in stages I to IV. The concentration of renalase in serum and urine was measured using an enzyme-linked immunosorbent assay (ELISA) kit (EIAab, Wuhan, China). We analyzed associations between renalase levels in urine and serum, and other parameters: sex, age, GFR, presence of hypertension, diabetes, and proteinuria, and determined the serum-to-urine renalase ratio and fractional excretion of renalase. Results Renalase and serum-to-urine ratio were significantly higher in CKD patients in comparison with the control group. Fractional excretion was lower in CKD patients but this difference did not reach the statistical significance (p = 0.092). Multivariate analysis performed in the CKD group showed, that from mentioned parameters, serum renalase was the only significant independent factor strongly positively associated with urinary renalase concentration. Conclusions The serum-to-urine ratio is significantly and about 6.5-fold higher in CKD patients, and the fractional excretion of renalase is 3-fold, but not significantly lower in CKD patients. Renalase levels in both serum and urine are not related to the glomerular filtration rate and not associated with blood pressure.
Collapse
Affiliation(s)
- Natalia M Serwin
- Department of Laboratory Medicine, Pomeranian Medical University, Szczecin, Poland.
| | - Magda Wiśniewska
- Department of Nephrology, Transplantology and Internal Diseases, Pomeranian Medical University, Szczecin, Poland
| | | | - Krzysztof Safranow
- Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Szczecin, Poland
| | - Edyta Skwirczyńska
- Department of History of Medicine and Medical Ethics, Pomeranian Medical University, Szczecin, Poland
| | - Barbara Dołęgowska
- Department of Laboratory Medicine, Pomeranian Medical University, Szczecin, Poland
| |
Collapse
|
6
|
Effects of renal denervation on blood-pressure response to hemorrhagic shock in spontaneously hypertensive rats. Chin J Traumatol 2018; 21:293-300. [PMID: 30342984 PMCID: PMC6235792 DOI: 10.1016/j.cjtee.2018.09.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Revised: 03/31/2018] [Accepted: 04/19/2018] [Indexed: 02/04/2023] Open
Abstract
PURPOSE Renal denervation (RD) has been demonstrated to be an effective approach to reduce blood pressure for those with resistant hypertension. Yet, we aimed to explore the effect and possible mechanism of RD on blood-pressure response to hemorrhagic shock in spontaneously hypertensive rats. METHODS A total of 48 male spontaneously hypertensive rats were randomized to three groups: study group, sham-operation group and control group. RD was achieved by cutting off renal nerves and swabbing phenol on it. Ten weeks after RD, 8 rats in each group were sacrificed to collect the kidney and heart tissues. The remaining rats were subjected to an operation to induce hemorrhagic shock which would lead to 40% loss of total blood volume, and observed for 120 min. The serum concentration of norepinephrine was measured before and three weeks after RD. RESULTS The blood-pressure and norepinephrine levels were reduced significantly after RD (p < 0.05). Systolic blood pressure and diastolic blood pressure of the surgery group were higher than those in the sham and control groups at 15, 30 and 45 min after hemorrhagic shock (p < 0.05), while no significant difference was observed at 60, 90 and 120 min (p > 0.05). Additionally, the beta-1 adrenergic receptor (β1-AR) in the study group was significantly higher than those in the other two groups (p < 0.05) after hemorrhagic shock. CONCLUSION This study demonstrated that RD could to some extent improve blood-pressure response to hemorrhagic shock in an established model of severe hemorrhagic shock in spontaneously hypertensive rats. The mechanism might be associated with up-regulation of β1-AR.
Collapse
|
7
|
Barber-Chamoux N, Esler MD. Predictive factors for successful renal denervation: should we use them in clinical trials? Eur J Clin Invest 2017; 47:860-867. [PMID: 28771706 DOI: 10.1111/eci.12792] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2017] [Accepted: 07/29/2017] [Indexed: 01/01/2023]
Abstract
Renal denervation (RDN) is facing various challenges to its initial claimed value in hypertension treatment. Major concerns are the choice of the patients and the technical efficacy of the RDN. Different factors have been described as predicting the capacity of RDN to decrease blood pressure. These factors are related to the patients, the procedure and the tools to confirm successful neural ablation. Their use in future trials should help to improve RDN trials understanding and outcomes. This review summarizes the different predictive factors available and their potential benefits in patient selection and in procedure guidance.
Collapse
Affiliation(s)
- Nicolas Barber-Chamoux
- Cardiology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.,Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Vic., Australia
| | - Murray D Esler
- Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Vic., Australia.,Heart Centre, Alfred Hospital, Melbourne, Vic., Australia
| |
Collapse
|
8
|
Chen W, Tang X, Yang X, Weng C, Yang K, Wen J, Liu H, Wu Y. Effects and Mechanisms of Radiofrequency Ablation of Renal Sympathetic Nerve on Anti-Hypertension in Canine. Arq Bras Cardiol 2017; 108:237-245. [PMID: 28273198 PMCID: PMC5389873 DOI: 10.5935/abc.20170014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Accepted: 08/31/2016] [Indexed: 12/24/2022] Open
Abstract
Background Radiofrequency ablation of renal sympathetic nerve (RDN) shows effective BP
reduction in hypertensive patients while the specific mechanisms remain
unclear. Objective We hypothesized that abnormal levels of norepinephrine (NE) and changes in
NE-related enzymes and angiotensinconverting enzyme 2 (ACE2), angiotensin
(Ang)-(1-7) and Mas receptor mediate the anti-hypertensive effects of
RDN. Methods Mean values of systolic blood pressure (SBP), diastolic blood pressure (DBP)
and mean arterial pressure (MAP) were assessed at baseline and follow-up.
Plasma and renal norepinephrine (NE) concentrations were determined using
highperformance liquid chromatography with electrochemical detection, and
levels of NE-related enzyme and ACE2-Ang(1-7)- Mas were measured using real
time PCR, Western blot and immunohistochemistry or Elisa in a hypertensive
canine model fed with high-fat diet and treated with RDN. The parameters
were also determined in a sham group treated with renal arteriography and a
control group fed with normal diet. Results RDN decreased SBP, DBP, MAP, plasma and renal NE. Compared with the sham
group, renal tyrosine hydroxylase (TH) expression was lower and renalase
expression was higher in the RDN group. Compared with the control group,
renal TH and catechol-o-methyl transferase (COMT) were higher and renalase
was lower in the sham group. Moreover, renal ACE2, Ang-(1-7) and Mas levels
of the RDN group were higher than those of the sham group, which were lower
than those of the control group. Conclusion RDN shows anti-hypertensive effect with reduced NE and activation of
ACE2-Ang(1-7)-Mas, indicating that it may contribute to the
anti-hypertensive effect of RDN.
Collapse
Affiliation(s)
- Wei Chen
- Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Xiaohong Tang
- Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Xiaofang Yang
- Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Chunyan Weng
- Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Kan Yang
- Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Juan Wen
- Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Hong Liu
- Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Yang Wu
- Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China
| |
Collapse
|
9
|
Gok Oguz E, Akoglu H, Ulusal Okyay G, Karaveli Gursoy G, Yildirim T, Merhametsiz O, Cimen T, Canbakan B, Yeter E, Ayli MD. Increased serum renalase in peritoneal dialysis patients: Is it related to cardiovascular disease risk? Nefrologia 2017; 37:189-194. [PMID: 28160962 DOI: 10.1016/j.nefro.2016.11.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2016] [Revised: 10/12/2016] [Accepted: 11/23/2016] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Renalase, with possible monoamine oxidase activity, is implicated in degradation of catecholamines; which suggests novel mechanisms of cardiovascular complications in patients with chronic kidney diseases. Epicardial adipose tissue (EAT) has been found to correlate with cardiovascular diseases (CVD) in dialysis patients. The present study aimed to evaluate the association of serum renalase levels with EAT thickness and other CVD risk factors in peritoneal dialysis (PD) patients. METHODS The study included 40 PD patients and 40 healthy controls. All subjects underwent blood pressure and anthropometric measurements. Serum renalase was assessed by using a commercially available assay. Transthoracic echocardiography was used to measure EAT thickness and left ventricular mass index (LVMI) in all subjects. RESULTS The median serum renalase level was significantly higher in the PD patients than in the control group [176.5 (100-278.3) vs 122 (53.3-170.0)ng/ml] (p=0.001). Renalase was positively correlated with C-reactive protein (r=0.705, p<0.001) and negatively correlated with RRF (r=-0.511, p=0.021). No correlation was observed between renalase and EAT thickness or LVMI. There was a strong correlation between EAT thickness and LVMI in both the PD patients and the controls (r=0.848, p<0.001 and r=0.640, p<0.001 respectively). CONCLUSIONS This study indicates that renalase is associated with CRP and residual renal function but not with EAT thickness as CVD risk factors in PD patients.
Collapse
Affiliation(s)
- Ebru Gok Oguz
- Diskapi Yildirim Beyazit Education and Research Hospital, Department of Nephrology, Ankara, Turkey.
| | - Hadim Akoglu
- Diskapi Yildirim Beyazit Education and Research Hospital, Department of Nephrology, Ankara, Turkey
| | - Gulay Ulusal Okyay
- Diskapi Yildirim Beyazit Education and Research Hospital, Department of Nephrology, Ankara, Turkey
| | - Guner Karaveli Gursoy
- Diskapi Yildirim Beyazit Education and Research Hospital, Department of Nephrology, Ankara, Turkey
| | - Tolga Yildirim
- Diskapi Yildirim Beyazit Education and Research Hospital, Department of Nephrology, Ankara, Turkey
| | - Ozgur Merhametsiz
- Diskapi Yildirim Beyazit Education and Research Hospital, Department of Nephrology, Ankara, Turkey
| | - Tolga Cimen
- Diskapi Yildirim Beyazit Education and Research Hospital, Department of Cardiology, Ankara, Turkey
| | - Basol Canbakan
- Diskapi Yildirim Beyazit Education and Research Hospital, Department of Nephrology, Ankara, Turkey
| | - Ekrem Yeter
- Diskapi Yildirim Beyazit Education and Research Hospital, Department of Cardiology, Ankara, Turkey
| | - M Deniz Ayli
- Diskapi Yildirim Beyazit Education and Research Hospital, Department of Nephrology, Ankara, Turkey
| |
Collapse
|
10
|
Sata Y, Schlaich MP. The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease. J Cardiovasc Pharmacol Ther 2016; 21:344-52. [PMID: 26740184 DOI: 10.1177/1074248415624156] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Accepted: 10/19/2015] [Indexed: 11/17/2022]
Abstract
Sympathetic activation is a hallmark of chronic and end-stage renal disease and adversely affects cardiovascular prognosis. Hypertension is present in the vast majority of these patients and plays a key role in the progressive deterioration of renal function and the high rate of cardiovascular events in this patient cohort. Augmentation of renin release, tubular sodium reabsorption, and renal vascular resistance are direct consequences of efferent renal sympathetic nerve stimulation and the major components of neural regulation of renal function. Renal afferent nerve activity directly influences sympathetic outflow to the kidneys and other highly innervated organs involved in blood pressure control via hypothalamic integration. Renal denervation of the kidney has been shown to reduce blood pressure in many experimental models of hypertension. Targeting the renal nerves directly may therefore be specifically useful in patients with chronic and end-stage renal disease. In this review, we will discuss the potential role of catheter-based renal denervation in patients with impaired kidney function and also reflect on the potential impact on other cardiovascular conditions commonly associated with chronic kidney disease such as heart failure and arrhythmias.
Collapse
Affiliation(s)
- Yusuke Sata
- Neurovascular Hypertension & Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute and the Heart Centre, Alfred Hospital, Melbourne, Australia
| | - Markus P Schlaich
- Neurovascular Hypertension & Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute and the Heart Centre, Alfred Hospital, Melbourne, Australia School of Medicine and Pharmacology-Royal Perth Hospital Unit, University of Western Australia, Perth, Australia
| |
Collapse
|
11
|
Wang Y, Xie BQ, Gao WH, Yan DY, Zheng WL, Lv YB, Cao YM, Hu JW, Yuan ZY, Mu JJ. Effects of Renin-Angiotensin System Inhibitors on Renal Expression of Renalase in Sprague-Dawley Rats Fed With High Salt Diet. Kidney Blood Press Res 2015; 40:605-13. [DOI: 10.1159/000368536] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/22/2015] [Indexed: 11/19/2022] Open
|
12
|
Abstract
BACKGROUND Contrast-induced acute kidney injury (CI-AKI) remains one of the crucial issues related to the development of invasive cardiology. The massive use of contrast media exposes patients to a great risk of contrast-induced nephropathy and chronic kidney disease development, and increases morbidity and mortality rates. The serum creatinine concentration does not allow for a timely and accurate CI-AKI diagnosis; hence numerous other biomarkers of renal injury have been proposed. Renalase, a novel catecholamine-metabolizing amine oxidase, is synthesized mainly in proximal tubular cells and secreted into urine and blood. It is primarily engaged in the degradation of circulating catecholamines. Notwithstanding its key role in blood pressure regulation, renalase remains a potential CI-AKI biomarker, which was shown to be markedly downregulated in the aftermath of renal injury. In this sense, renalase appears to be the first CI-AKI marker revealing an actual loss of renal function and indicating disease severity. SUMMARY The purpose of this review is to summarize the contemporary knowledge about the application of novel biomarkers of CI-AKI and to highlight the potential role of renalase as a functional marker of contrast-induced renal injury. KEY MESSAGES Renalase may constitute a missing biochemical link in the mutual interplay between kidney and cardiac pathology known as the cardiorenal syndrome.
Collapse
Affiliation(s)
- Maciej T Wybraniec
- First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
| | - Katarzyna Mizia-Stec
- First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
| |
Collapse
|
13
|
Wybraniec MT, Czerwieńska B, Lelek M, Adamczak M, Więcek A, Mizia-Stec K. Plasma renalase concentration before and after radiofrequency renal denervation in patients with resistant hypertension. J Hum Hypertens 2015; 30:410-1. [DOI: 10.1038/jhh.2015.94] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
14
|
Malyszko J, Bachorzewska-Gajewska H, Dobrzycki S. Renalase, kidney and cardiovascular disease: are they related or just coincidentally associated? Adv Med Sci 2015; 60:41-9. [PMID: 25461379 DOI: 10.1016/j.advms.2014.10.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2014] [Revised: 09/15/2014] [Accepted: 10/10/2014] [Indexed: 12/15/2022]
Abstract
Cardiovascular diseases, including hypertension are the leading cause of death in the developed countries. Diabetes and chronic kidney disease became also more prevalent reaching almost the level of epidemy. Researchers are looking eagerly for the new risk and/or pathogenetic factors, as well as therapeutic option in these disease. It has been suggested that human kidney releases a protein named renalase into the bloodstream. It is supposed to be an enzyme which breaks down catecholamines in the blood circulation and regulate blood pressure. However, there were several doubts whether renalase exerts monoaminooxidase activity, or if it is monoaminooxidase at all. Recently, a hypothesis that it is also a cytokine was postulated. Studies on renalase polymorphisms in hypertension, cardiovascular disease or diabetes are inconsistent. Similarly, there are several discrepancies in the animal on the possible role of renalase in hypertension and cardiovascular diseases. Some studies report a protective role of renalase in acute kidney injury, whereas others showed that renalase levels were mainly dependent on kidney function, indicating rather a role of kidney in excretion of this substance. Moreover, validated assays are needed to evaluate renalase levels and activity. On one hand a deeper and more accurate link between renalase and cardiovascular diseases require further profound research, on the other hand whether or not renalase protein could be a new therapeutic target in these pathologies should also be considered. Whether renalase, discovered in 2005, might be a Holy Grail of hypertension, linking kidney and cardiovascular diseases, remains to be proven.
Collapse
Affiliation(s)
- Jolanta Malyszko
- 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland.
| | | | - Slawomir Dobrzycki
- Invasive Cardiology Department, Medical University of Bialystok, Bialystok, Poland
| |
Collapse
|
15
|
Zhao Q, Huang H, Wang X, Wang X, Dai Z, Wan P, Guo Z, Yu S, Tang Y, Huang C. Changes of serum neurohormone after renal sympathetic denervation in dogs with pacing-induced heart failure. Int J Clin Exp Med 2014; 7:4024-4030. [PMID: 25550911 PMCID: PMC4276169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2014] [Accepted: 09/20/2014] [Indexed: 06/04/2023]
Abstract
BACKGROUND Neurohormonal activation is a commonly cited array of phenomena in the body's physiologic response to heart failure (HF). The aim of the present study was to determine the change law of serum neurohormones after renal sympathetic denervation (RSD) in dogs with pacing-induced HF. METHODS Twenty-eight beagles were randomly divided into control group, RSD group, HF group and HF + RSD group. The control group was implanted pacemakers without pacing; the RSD group underwent renal artery ablation without pacing; the HF group was implanted pacemakers with ventricular pacing at 240 bpm for 3 weeks; and HF + RSD group underwent renal artery ablation and with ventricular pacing at 240 bpm for 3 weeks. Blood samples were taken at baseline, and 3, 6, 9, 12, 15, 18, 21 days in all the dogs for neurohormones measurement. RESULTS After 3 weeks, the systolic femoral artery pressures in the HF and HF + RSD groups were reduced after pacing 3 weeks. There was an increase significantly in BNP, angiotensin II, aldosterone, endothelin-1 and decrease in renalase after 3 weeks when compared with baseline in HF group. RSD significantly suppressed the changes of plasma neurohormones concentration in experimental HF, but RSD had not obviously impact on the levels of plasma neurohormones during 3 weeks in RSD group. CONCLUSIONS RSD attenuates the changes of levels of plasma neurohormones in the activated renin-angiotensin-aldosterone system (RAAS) but had not obviously effect in the normal physiology of RAAS.
Collapse
Affiliation(s)
- Qingyan Zhao
- Cardiovascular Research Institute of Wuhan University, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan City 430060, P. R. of China
| | - He Huang
- Cardiovascular Research Institute of Wuhan University, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan City 430060, P. R. of China
| | - Xule Wang
- Cardiovascular Research Institute of Wuhan University, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan City 430060, P. R. of China
| | - Xiaozhan Wang
- Cardiovascular Research Institute of Wuhan University, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan City 430060, P. R. of China
| | - Zixuan Dai
- Cardiovascular Research Institute of Wuhan University, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan City 430060, P. R. of China
| | - Peixing Wan
- Cardiovascular Research Institute of Wuhan University, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan City 430060, P. R. of China
| | - Zongwen Guo
- Cardiovascular Research Institute of Wuhan University, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan City 430060, P. R. of China
| | - Shengbo Yu
- Cardiovascular Research Institute of Wuhan University, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan City 430060, P. R. of China
| | - Yanhong Tang
- Cardiovascular Research Institute of Wuhan University, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan City 430060, P. R. of China
| | - Congxin Huang
- Cardiovascular Research Institute of Wuhan University, Renmin Hospital of Wuhan University 238 Jiefang Road, Wuhan City 430060, P. R. of China
| |
Collapse
|
16
|
Sonawane PJ, Gupta V, Sasi BK, Kalyani A, Natarajan B, Khan AA, Sahu BS, Mahapatra NR. Transcriptional regulation of the novel monoamine oxidase renalase: Crucial roles of transcription factors Sp1, STAT3, and ZBP89. Biochemistry 2014; 53:6878-92. [PMID: 25295465 DOI: 10.1021/bi500798n] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Renalase, a novel monoamine oxidase, is emerging as an important regulator of cardiovascular, metabolic, and renal diseases. However, the mechanism of transcriptional regulation of this enzyme remains largely unknown. We undertook a systematic analysis of the renalase gene to identify regulatory promoter elements and transcription factors. Computational analysis coupled with transfection of human renalase promoter/luciferase reporter plasmids (5'-promoter-deletion constructs) into various cell types (HEK-293, IMR32, and HepG2) identified two crucial promoter domains at base pairs -485 to -399 and -252 to -150. Electrophoretic mobility shift assays using renalase promoter oligonucleotides with and without potential binding sites for transcription factors Sp1, STAT3, and ZBP89 displayed formation of specific complexes with HEK-293 nuclear proteins. Consistently, overexpression of Sp1, STAT3, and ZBP89 augmented renalase promoter activity; additionally, siRNA-mediated downregulation of Sp1, STAT3, and ZBP89 reduced the level of endogenous renalase transcription as well as the transfected renalase promoter activity. In addition, chromatin immunoprecipitation assays showed in vivo interactions of these transcription factors with renalase promoter. Interestingly, renalase promoter activity was augmented by nicotine and catecholamines; while Sp1 and STAT3 synergistically activated the nicotine-induced effect, Sp1 appeared to enhance epinephrine-evoked renalase transcription. Moreover, renalase transcript levels in mouse models of human essential hypertension were concomitantly associated with endogenous STAT3 and ZBP89 levels, suggesting crucial roles for these transcription factors in regulating renalase gene expression in cardiovascular pathological conditions.
Collapse
Affiliation(s)
- Parshuram J Sonawane
- Cardiovascular Genetics Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras , Chennai 600036, India
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Wang F, Cai H, Zhao Q, Xing T, Li J, Wang N. Epinephrine Evokes Renalase Secretion via a-Adrenoceptor/NF-κB Pathways in Renal Proximal Tubular Epithelial Cells. Kidney Blood Press Res 2014; 39:252-9. [DOI: 10.1159/000355802] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/02/2014] [Indexed: 11/19/2022] Open
|
18
|
Wang Y, Liu FQ, Wang D, Mu JJ, Ren KY, Guo TS, Chu C, Wang L, Geng LK, Yuan ZY. Effect of salt intake and potassium supplementation on serum renalase levels in Chinese adults: a randomized trial. Medicine (Baltimore) 2014; 93:e44. [PMID: 25058146 PMCID: PMC4602427 DOI: 10.1097/md.0000000000000044] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Renalase, a recently discovered enzyme released by the kidneys, breaks down blood-borne catecholamines and may thus regulate blood pressure (BP). Animal studies have suggested that high levels of dietary salt might reduce blood and kidney renalase levels. We conducted a randomized trial to assess the effects of altered salt and potassium intake on serum renalase levels and the relationship between serum renalase levels and BP in humans.Forty-two subjects (28-65 years of age) were selected from a rural community of northern China. All subjects were sequentially maintained on a low-salt diet for 7 days (3.0 g/day of NaCl), a high-salt diet for additional 7 days (18.0 g/day of NaCl), and a high-salt diet with potassium supplementation for final 7 days (18.0 g/day of NaCl + 4.5 g/day of KCl).Serum renalase levels were significantly higher than baseline levels during the low-salt diet intervention period. Renalase levels decreased with the change from the low-salt to high-salt diet, whereas dietary potassium prevented the decrease in serum renalase induced by the high-salt diet. There was a significant inverse correlation between the serum renalase level and 24-h urinary sodium excretion. No significant correlation was found between the renalase level and BP among the different dietary interventions.The present study indicates that variations in dietary salt intake and potassium supplementation affect the serum renalase concentration in Chinese subjects.
Collapse
Affiliation(s)
- Yang Wang
- Cardiovascular Department (YW, F-QL, DW, J-JM, K-YR, T-SG, CC, LW, L-KG, Z-YY), First Affiliated Hospital of Medical College, Xi'an Jiaotong University; and Key Laboratory of Environment and Genes Related to Diseases (YW, F-QL, DW, J-JM, K-YR, T-SG, CC, LW, Z-YY), Ministry of Education, Xi'an, P.R. China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Pawlik A, Serdynska M, Dabrowska-Zamojcin E, Dziedziejko V, Safranow K, Domanski L, Ciechanowski K. Renalase Gene Polymorphism in Patients After Renal Allograft Transplantation. Kidney Blood Press Res 2014; 39:58-64. [DOI: 10.1159/000355777] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/08/2014] [Indexed: 11/19/2022] Open
|
20
|
Li X, Jiang W, Li L, Huang R, Yang Q, Yang Y, Hong Y, Tang X. Renalase gene polymorphism in patients with hypertension and concomitant coronary heart disease. Kidney Blood Press Res 2014; 39:9-16. [PMID: 24821235 DOI: 10.1159/000355771] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/28/2014] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND/AIMS This study aimed to investigate renalase gene polymorphism in patients with hypertension and concomitant coronary heart disease (CHD) and to evaluate the risk for CHD in hypertensive patients from the view of genetics. METHODS NCBI and HapMap genome database were employed to screen the Single nucleotide polymorphisms (SNP). These SNPs were detected in hypertensive and CHD patients (n=791), hypertensive patients (n=802) and healthy controls (n=812), and the genotypes were recorded. Haploview 4.2 software was used to determine the genotypes, allele frequency, haplotypes, linkage disequilibrium and Hardy-Weinberg (HWE) equilibrium, and odds ratio (OR) was calculated with non-conditioned logistic regression analysis. RESULTS The frequency of allele A of rs2576178 in patients with hypertensive and CHD was markedly higher than that in hypertensive patients (p=0.001, OR=1.625,95% CI 1.221-2.160). The frequency of allele C of rs2296545 in hypertensive patients was significantly higher than that in healthy controls (P=0.009, OR=1.436, 95% CI 1.095-1.883). CONCLUSION The allele A of rs2576178 may be a predisposing factor of CHD in hypertensive patients, and hypertensive patients with AA genotype are susceptible to develop CHD. The allele C of rs2296545 may be a predisposing factor of hypertension and patients with CC genotype are susceptible to develop hypertension.
Collapse
Affiliation(s)
- Xiaogang Li
- Department of Cardiovascular Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Li X, Huang R, Xie Z, Lin M, Liang Z, Yang Y, Jiang W. Renalase, a new secretory enzyme: Its role in hypertensive-ischemic cardiovascular diseases. Med Sci Monit 2014; 20:688-92. [PMID: 24762661 PMCID: PMC4005863 DOI: 10.12659/msm.890261] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Abstract Renalase, a novel amine oxidase, is mainly expressed in the kidney, heart, and skeletal muscle. It has been known to degrade circulating catecholamines and plays a crucial role in human diseases. Recent studies have demonstrated its structure, unique bioactivities, function, and the gene polymorphisms in human diseases. In this review, we summarize the effects of renalase on hypertension, myocardial ischemia, acute kidney injury (AKI), ischemic stroke, cardiac dysfunction, organ transplantation, and diabetes mellitus reported in numerous studies.
Collapse
Affiliation(s)
- Xiaogang Li
- Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, China (mainland)
| | - Ruixia Huang
- Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, China (mainland)
| | - Zijian Xie
- Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, China (mainland)
| | - Mingyuan Lin
- Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, China (mainland)
| | - Zhongshu Liang
- Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, China (mainland)
| | - Yan Yang
- Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, China (mainland)
| | - Weihong Jiang
- Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, China (mainland)
| |
Collapse
|
22
|
Abstract
Renalase, a recently discovered flavoprotein, which is strongly expressed in the kidney and heart, effectively metabolizes catecholamines. It was discovered during the search to identify proteins secreted by the kidney that could help explain the high incidence of cardiovascular disease in patients with chronic kidney disease. Recent advances have led to more detailed knowledge of its biology, structure, enzymatic activity, mechanisms of action, associations with human disease states and potential therapeutic value. In this study, we review these advances with a focus on hypertension and kidney disease.
Collapse
Affiliation(s)
- Gary V Desir
- Medical Service, VA Connecticut Healthcare System, West Haven, CT, USA
| | | |
Collapse
|
23
|
Fedchenko V, Globa A, Buneeva O, Medvedev A. Renalase mRNA levels in the brain, heart, and kidneys of spontaneously hypertensive rats with moderate and high hypertension. Med Sci Monit Basic Res 2013; 19:267-70. [PMID: 24113803 PMCID: PMC3808184 DOI: 10.12659/msmbr.889540] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Background Renalase is a recently discovered secretory protein involved in regulation of arterial blood pressure in humans and animals. Results of animal experiments from independent laboratories indicate that administration of human recombinant renalase decreases blood pressure and some genetically predisposed hypertensive rats have lowered renalase levels. Material/Methods The levels of renalase mRNA expression in brain hemispheres, heart, and kidneys of spontaneously hypertensive rats (SHR) with moderate (140–180 mm Hg) or high (>180 mm Hg) hypertension and of control Wistar-Kyoto (WKY) rats were analyzed using real-time PCR. Results Spontaneously hypertensive rats with high hypertension (>180 mm Hg) had a lower renalase mRNA level in brain hemispheres, and higher heart and kidney renalase mRNA levels compared with control WKY rats. In SHR with a moderate increase in arterial blood pressure (140–180 mm Hg), the tissue renalase mRNA changed in the same direction but did not reach the level of statistical significance as compared with control rats. Conclusions The results indicate that the development of hypertension in SHR is accompanied by altered expression of the renalase gene in the examined organs as compared with control WKY rats. The brain and peripheral tissues renalase mRNA levels demonstrate opposite trends, which are obviously crucial for impaired regulation of blood pressure in SHR.
Collapse
Affiliation(s)
- Valerii Fedchenko
- Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia
| | | | | | | |
Collapse
|
24
|
Lee HT, Kim JY, Kim M, Wang P, Tang L, Baroni S, D'Agati VD, Desir GV. Renalase protects against ischemic AKI. J Am Soc Nephrol 2013; 24:445-55. [PMID: 23393318 DOI: 10.1681/asn.2012090943] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Elevated levels of plasma catecholamines accompany ischemic AKI, possibly contributing the inflammatory response. Renalase, an amine oxidase secreted by the proximal tubule, degrades circulating catecholamines and reduces myocardial necrosis, suggesting that it may protect against renal ischemia reperfusion injury. Here, mice subjected to renal ischemia reperfusion injury had significantly lower levels of renalase in the plasma and kidney compared with sham-operated mice. Consistent with this, plasma NE levels increased significantly after renal ischemia reperfusion injury. Furthermore, renal tubular inflammation, necrosis, and apoptosis were more severe and plasma catecholamine levels were higher in renalase-deficient mice subjected to renal ischemia reperfusion compared with wild-type mice. Administration of recombinant human renalase reduced plasma catecholamine levels and ameliorated ischemic AKI in wild-type mice. Taken together, these data suggest that renalase protects against ischemic AKI by reducing renal tubular necrosis, apoptosis, and inflammation, and that plasma renalase might be a biomarker for AKI. Recombinant renalase therapy may have potential for the prevention and treatment of AKI.
Collapse
Affiliation(s)
- H Thomas Lee
- Department of Anesthesiology, Anesthesiology Research Laboratories, College of Physicians and Surgeons, Columbia University, P&S Box 46 (PH-5), 630 West 168th Street, New York, NY 10032-3784, USA.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Desir GV, Wang L, Peixoto AJ. Human renalase: a review of its biology, function, and implications for hypertension. ACTA ACUST UNITED AC 2012; 6:417-26. [DOI: 10.1016/j.jash.2012.09.002] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2012] [Accepted: 09/18/2012] [Indexed: 02/04/2023]
|
26
|
Wang F, Xing T, Li J, Bai M, Hu R, Zhao Z, Tian S, Zhang Z, Wang N. Renalase's expression and distribution in renal tissue and cells. PLoS One 2012; 7:e46442. [PMID: 23056310 PMCID: PMC3463591 DOI: 10.1371/journal.pone.0046442] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2012] [Accepted: 08/30/2012] [Indexed: 12/19/2022] Open
Abstract
To study renalase's expression and distribution in renal tissues and cells, renalase coded DNA vaccine was constructed, and anti-renalase monoclonal antibodies were produced using DNA immunization and hybridoma technique, followed by further investigation with immunological testing and western blotting to detect the expression and distribution of renalase among the renal tissue and cells. Anti-renalase monoclonal antibodies were successfully prepared by using DNA immunization technique. Further studies with anti-renalase monoclonal antibody showed that renalase expressed in glomeruli, tubule, mesangial cells, podocytes, renal tubule epithelial cells and its cells supernatant. Renalase is wildly expressed in kidney, including glomeruli, tubule, mesangial cells, podocytes and tubule epithelial cells, and may be secreted by tubule epithelial cells primarily.
Collapse
Affiliation(s)
- Feng Wang
- Department of Nephrology and Rheumatology, Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University, Shanghai, China
- * E-mail: (FW); (NW)
| | - Tao Xing
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Australia
| | - Junhui Li
- Department of Nephrology and Rheumatology, Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University, Shanghai, China
| | - Mei Bai
- Department of Nephrology and Rheumatology, Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University, Shanghai, China
| | - Ruimin Hu
- Department of Pathology, Shanghai Medical College, Fudan Univesity, Shanghai, China
| | - Zhonghua Zhao
- Department of Pathology, Shanghai Medical College, Fudan Univesity, Shanghai, China
| | - Shoufu Tian
- Department of Nephrology and Rheumatology, Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University, Shanghai, China
| | - Zhigang Zhang
- Department of Pathology, Shanghai Medical College, Fudan Univesity, Shanghai, China
| | - Niansong Wang
- Department of Nephrology and Rheumatology, Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University, Shanghai, China
- * E-mail: (FW); (NW)
| |
Collapse
|